# Clinical Trial Assessing the Efficacy of Abscopal Effect Induced by SBRT and Immunotherapy in Advanced NSCLC

> **NCT04238169** · PHASE2 · COMPLETED · sponsor: **Xinqiao Hospital of Chongqing** · enrollment: 60 (actual)

## Conditions studied

- Non-Small-Cell Lung Cancer Stage IV

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Toripalimab
- **RADIATION:** SBRT

## Key facts

- **NCT ID:** NCT04238169
- **Lead sponsor:** Xinqiao Hospital of Chongqing
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-01
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2024-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04238169

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04238169, "Clinical Trial Assessing the Efficacy of Abscopal Effect Induced by SBRT and Immunotherapy in Advanced NSCLC". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04238169. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*